Key Developments: Nanosphere Inc (NSPH.PH)

NSPH.PH on Philadelphia Stock Exchange

0.31USD
27 Feb 2015
Change (% chg)

$0.02 (+6.06%)
Prev Close
$0.30
Open
$0.33
Day's High
$0.34
Day's Low
$0.31
Volume
549
Avg. Vol
689
52-wk High
$2.61
52-wk Low
$0.23

Search Stocks

Latest Key Developments (Source: Significant Developments)

Nanosphere Inc gives FY 2015 revenue guidance below analysts' estimates
Wednesday, 11 Feb 2015 04:01pm EST 

Nanosphere Inc:Says revenue guidance for FY 2015 set at $18 million to $20 million.FY 2015 revenue of $23 million - Thomson Reuters I/B/E/S.  Full Article

Nanosphere Inc announces receipt of FDA warning letter
Wednesday, 28 Jan 2015 04:00pm EST 

Nanosphere Inc:Receives a warning letter from the FDA resulting from inspections of the company's facility in Northbrook, Illinois by the FDA's Chicago District Office that occurred in March 2014.Says the warning letter relates to deficiencies in the company's quality system regulation.Nanosphere takes this matter seriously and is in the process of evaluating the corrective actions required to address the matters raised in the warning letter.Nanosphere also is in the process of preparing a response to the warning letter and intends to respond fully to the issues raised by the FDA within 15 business days as requested by the FDA, and to work diligently and expeditiously to resolve the issues raised by the FDA.  Full Article

Nanosphere Inc announces management changes
Wednesday, 28 Jan 2015 04:00pm EST 

Nanosphere Inc:Announced that on Jan. 26, Roger Moody notified Nanosphere that he would be stepping down as Nanosphere's Chief Financial Officer effective on Feb. 11.In connection with Mr. Moody's resignation, Nanosphere has appointed Ann Wallin, Nanosphere's Vice President of Finance and Accounting, as interim Chief Financial Officer and as Chief Accounting Officer effective Feb. 11.Also effective Jan. 26, Sheli Z. Rosenberg, Nanosphere's Chair of the Board of Directors, advised the company that she has resigned from the Board of Directors.  Full Article

Nanosphere Inc announces closing of common stock offering
Monday, 27 Oct 2014 04:01pm EDT 

Nanosphere Inc:Announced the closing of its previously announced underwritten public offering of 40,000,000 shares of its common stock at a public offering price of $0.50 per share.Chardan Capital Markets, LLC acted as the sole book-running manager for the offering.Net proceeds from the sale of the shares after underwriting discounts and commissions and other offering expenses are expected to be about $18.4 million.  Full Article

Nanosphere Inc prices $20 million public offering of common stock
Wednesday, 22 Oct 2014 09:00am EDT 

Nanosphere Inc:Says pricing of its previously said underwritten public offering of 40,000,000 shares of its common stock at public offering price of $0.50 per share.Granted underwriters 30-day option to purchase up to an additional 6,000,000 shares of common stock to cover over-allotments, if any.Chardan Capital Markets, LLC is acting as sole book-running manager for offering.Net proceeds from sale of shares of common stock after underwriting discounts and commissions and other offering expenses are expected to be about $18.4 mln.Offering is subject to customary closing conditions and is expected to close on Oct. 27.Use net proceeds from offering for general corporate purposes and working capital.  Full Article

Nanosphere announces commencement of public offering of common stock
Tuesday, 21 Oct 2014 04:01pm EDT 

Nanosphere Inc:Commences an underwritten public offering of its common stock.Chardan Capital Markets, LLC is acting as the sole book-running manager for the offering.Plans to use the net proceeds from the offering for general corporate purposes and working capital.  Full Article

New outcomes data presented at ICAAC 2014 further validates clinical and economic utility of Nanosphere Inc 's verigene blood culture test
Monday, 8 Sep 2014 08:01am EDT 

Nanosphere Inc:Says data from three outcomes studies demonstrating clinical and economic impact of the Verigene Gram-Positive Blood Culture Nucleic Acid Test (BC-GP) for rapid sepsis diagnostic testing were presented.Says each of the three outcomes studies presented showed that Verigene BC-GP, when paired with active antimicrobial stewardship program involvement, made a significant impact on patient care.Says all studies reported a reduction in time to optimal antimicrobial therapy, with two studies reporting an average decrease of over 20 hours.Says two of these studies demonstrated an average intensive-care unit (ICU) length-of-stay (LOS) reduction of at least 2.5 days.Says one study demonstrated a 3 month net cost savings of $153,000 by implementing Verigene BC-GP, the authors to forecast a savings of $612,000 for the full year.Says study also demonstrated a trend toward reduction in 30 day mortality by nearly 6 pct.Says mean hospital LOS decreased by 1.3 days and ICU LOS by 3.5 days, leading to an estimated annual net savings of $612,000.  Full Article

Nanosphere Inc announces new clinical and economic outcome data for verigene blood culture test to be presented at ICAAC 2014
Tuesday, 2 Sep 2014 08:00am EDT 

Nanosphere Inc:Says three outcomes studies demonstrating clinical and economic impact of Verigene Gram-Positive Blood Culture Nucleic Acid Test (BC-GP) will be presented on Antimicrobial Agents and Chemotherapy (ICAAC), to be held in Washington, DC on Sept. 5 - 9.Says each of the three studies paired Verigene BC-GP for rapid sepsis diagnostic testing with active antimicrobial stewardship programs to assess the impact on antimicrobial optimization and patient outcomes.Says settings included two teaching institutions and non-teaching community hospital.  Full Article

Nanosphere Inc lowers FY 2014 revenue guidance
Wednesday, 6 Aug 2014 04:01pm EDT 

Nanosphere Inc:Resets FY 2014 guidance to $14 million in revenue, down from the previous guidance of $19 million to $21 million.FY 2014 revenue of $19 million - Thomson Reuters I/B/E/S.  Full Article

Nanosphere Inc's verigene enteric pathogens test receives FDA clearance
Tuesday, 24 Jun 2014 06:00pm EDT 

Nanosphere Inc:Receives U.S. Food and Drug Administration (FDA) 510(k) clearance for the bacterial portion of its Verigene┬« Enteric Pathogens Nucleic Acid Test (EP).Clinical studies for the full panel, including two additional viral targets, have been completed and the Company expects clearance of the full EP panel.  Full Article

Search Stocks